Imperative Care has announced US Food and Drug Administration (FDA) 510(k) clearance for its latest advancement in ischaemic stroke treatment, the Zoom 7X aspiration thrombectomy catheter, in addition to the first patient cases with this novel technology.
A company press release details that, as the newest addition to its comprehensive Zoom stroke system, the Zoom 7X catheter is the first catheter to incorporate CenTRX technology—a unique, 96-degree, pre-shaped tip designed to centre in the vessel in order to maximise clot ingestion owing to the extra surface area of the asymmetric tip. This proprietary feature allows the device to navigate challenging anatomy and self-orient its geometric tip into the optimal position for full clot aspiration, building upon the benefits of asymmetric aspiration in stroke, according to Imperative.
“I’ve seen significant benefit in using a shaped asymmetric tip for my stroke procedures,” said Jacob Cherian (University of Maryland, College Park, USA). “I believe the tip of Zoom 7X allows the catheter to self-orient from within the centre of the vessel for enhanced trackability. This capability, along with a full system approach from 0.088-inch intracranial access to complete clot ingestion, has helped further streamline my procedures. I’m encouraged to see Imperative Care respond to feedback from the physician community to engineer a solution that I expect will bring notable improvements to procedure efficiency and speed.”
“Based on my early experience with Zoom 7X, I anticipate this new tip configuration will help reduce the need for extra devices and simplify my thrombectomy procedures, leading to faster access and case times,” added Keith Woodward (Fort Sanders Regional Medical Center, Knoxville, USA). “Having new options to access and navigate challenging anatomy is key to making stroke treatment fast and reliable.”
“Based on direct feedback from physicians, the Zoom 7X catheter was developed to address the need for even greater trackability, navigation and asymmetric clot ingestion,” commented Ariel Sutton, general manager of stroke at Imperative. “Zoom 7X builds upon our comprehensive system of stroke technologies with the goal of making the procedure faster, safer and more efficient than ever before. The launch of Zoom 7X—paired with the recent introduction of the continuous dual aspiration technique (CDAT) with Zoom DuoPort—advances the field one step closer to making TICI [thrombolysis in cerebral infarction] 3 in 10 minutes the expectation for physicians.”
